Skip to content
Nonprofiteer
← NATIONAL ATAXIA FOUNDATION INC

Form 990 for tax year 2023

Filed by NATIONAL ATAXIA FOUNDATION INC.

Totals

Total revenue
$3,981,625
Total expenses
$4,863,570
Contributions and grants received
$3,083,219
Grants paid
$1,749,340
Program service revenue
$835,649
Investment income
$73,728
Other revenue
-$10,971
Total assets, end of year
$4,116,826
Total liabilities, end of year
$501,880
Net assets or fund balances, end of year
$3,614,946
Program services expenses (Part IX)
$3,787,844
Management and general expenses
$538,078
Fundraising expenses
$537,648
Program service expenses (Part III)
$3,787,844

Program services were 77.9% of total expenses calculated — Part IX's program-services column over total expenses, both as filed.

Line items

Every line the filer filed in Parts VIII, IX and X, as filed and in filed order. Blank columns are left out, and the lines are not forced to add up to the totals above.

Revenue

Part VIII, the statement of revenue.

  • 1c · Fundraising events

    $238,837

  • 1f · All other contributions, gifts and grants

    $2,844,382

  • 2a · Program service revenue: Drug Development Colla

    total $570,833 · related or exempt $570,833

  • 2b · Program service revenue: Conference income

    total $264,816 · related or exempt $264,816

  • 3 · Investment income

    total $73,728 · excluded $73,728

  • 8a · Fundraising events: gross income

    $0

  • 8a · Fundraising events: contributions included on line 1c

    $238,837

  • 8b · Fundraising events: direct expenses

    $10,971

  • 8c · Net income from fundraising events

    total -$10,971 · excluded -$10,971

Functional expenses

Part IX, the statement of functional expenses.

  • 1 · Grants to domestic organizations and governments

    total $1,318,020 · program services $1,318,020

  • 2 · Grants to domestic individuals

    total $26,520 · program services $26,520

  • 3 · Grants to foreign organizations and individuals

    total $404,800 · program services $404,800

  • 5 · Compensation of officers, directors and key employees

    total $553,270 · program services $387,299 · management and general $53,417 · fundraising $112,554

  • 7 · Other salaries and wages

    total $922,520 · program services $648,075 · management and general $87,822 · fundraising $186,623

  • 9 · Other employee benefits

    total $146,488 · program services $94,943 · management and general $18,271 · fundraising $33,274

  • 10 · Payroll taxes

    total $109,128 · program services $77,686 · management and general $9,732 · fundraising $21,710

  • 11a · Fees: management

    total $91,671 · program services $43,151 · management and general $38,198 · fundraising $10,322

  • 11b · Fees: legal

    total $5,640 · program services $5,640

  • 11c · Fees: accounting

    total $15,605 · management and general $15,605

  • 11g · Fees: other

    total $111,339 · program services $52,409 · management and general $46,393 · fundraising $12,537

  • 12 · Advertising and promotion

    total $87,615 · program services $11,925 · management and general $45,852 · fundraising $29,838

  • 13 · Office expenses

    total $51,076 · program services $8,889 · management and general $31,985 · fundraising $10,202

  • 16 · Occupancy

    total $63,895 · management and general $63,895

  • 19 · Conferences, conventions and meetings

    total $804,642 · program services $690,799 · management and general $44,865 · fundraising $68,978

  • 23 · Insurance

    total $12,931 · management and general $12,931

  • 24a · Other expenses: Dues and subscriptions

    total $80,410 · program services $8,106 · management and general $22,422 · fundraising $49,882

  • 24b · Other expenses: Bank and credit card fe

    total $48,615 · program services $4,924 · management and general $43,691

  • 24c · Other expenses: Miscellaneous

    total $5,008 · program services $3,640 · management and general $140 · fundraising $1,228

  • 24d · Other expenses: Professional developmen

    total $4,377 · program services $1,018 · management and general $2,859 · fundraising $500

Balance sheet

Part X, book values.

  • 1 · Cash, non-interest-bearing

    beginning of year $1,969,164 · end of year $550,112

  • 2 · Savings and temporary cash investments

    beginning of year $1,642,051 · end of year $468,613

  • 4 · Accounts receivable

    beginning of year $55,331 · end of year $6,438

  • 9 · Prepaid expenses and deferred charges

    beginning of year $187,070 · end of year $255,729

  • 11 · Investments: publicly traded securities

    beginning of year $1,065,945 · end of year $2,778,614

  • 15 · Other assets

    beginning of year $89,034 · end of year $57,320

  • 17 · Accounts payable and accrued expenses

    beginning of year $470,035 · end of year $333,967

  • 19 · Deferred revenue

    beginning of year $22,291 · end of year $109,810

  • 25 · Other liabilities

    beginning of year $89,652 · end of year $58,103

  • 27 · Net assets without donor restrictions

    beginning of year $2,404,811 · end of year $934,379

  • 28 · Net assets with donor restrictions

    beginning of year $2,021,806 · end of year $2,680,567

Mission and programs · 2023

Mission

The National Ataxia Foundation's mission is to accelerate the development of treatments and a cure while working to improve the lives of those living with Ataxia.

Activities or mission (Part I)

To accelerate the development of treatments and a cure while working to improve the lives of those living with Ataxia.

  • The National Ataxia Foundation offers patient education, advocacy, and support programs to improve the lives of those living with Ataxia. NAF's patient education program provides an annual conference, webinars, and fact sheets to help individuals manage their health and quality of life. NAF's advocacy program involves policy makers and pharmaceutical companies to grow awareness of Ataxia, accelerate drug development and ensure access to care and treatment services. NAF's support group program offers a way for the Ataxia community to connect and learn from others.

    Expenses $1,037,255 · Grants $26,520 · Revenue $264,816

  • NAF is committed to funding cutting-edge basic and translational research into hereditary and sporadic ataxia. The goals of NAF's research program are to further elucidate the disease mechanisms of ataxias, bring early-career clinicians and scientists into ataxia research, and help drive the field towards developing treatments and a cure for ataxia. Annual grants are selected through a competitive review process that includes NAF's Medical and Research Advisory Board members and over 80 leading ataxia scientists and clinicians, both domestic and international. Each year NAF awards grants to researchers from domestic and international non-profit and for-profit institutions that directly support basic and translational ataxia research through the following funding mechanisms:1. Pioneer SCA3 Translational Research Awards: Annually granted to outstanding research proposals that aim to make significant advancements in the development of treatments and/or improvements to patient care for Spinocerebellar Ataxia Type 3 (SCA3). Proposals may incorporate other forms of ataxia but must have a predominant focus on SCA3 translational or clinical research. 2. Seed Money Research Grant: Granted primarily as "seed monies" to assist investigators in the early or pilot phase of their studies and as additional support for ongoing investigations on demonstration of need. It is hoped that these studies will be further developed to attract future funding from other sources. 3. Post-doctoral Fellowship Award: Post-doctoral fellowship awards are to serve as a bridge from post-doctoral positions to junior faculty positions. Applicants should have completed at least one year of post-doctoral training, but not more than two at the time of application and should have shown a commitment to research in the field of ataxia. The award will permit individuals to spend an additional third year in a post-doctoral position and increase chances to establish an independent ataxia research program.4. Early Career Investigator Award: The Early Career Investigator Award was created to encourage early career clinical and scientific investigators to pursue a career in the field of ataxia research. 5. Pre-doctoral Fellowship to Promote Diversity in Ataxia Research: Merit-based award intended to enhance research and/or clinical training of promising graduate students from historically underrepresented backgrounds who are matriculated in pre-doctoral or clinical health professional degree training programs and who intend careers as scientists or other clinician-scientists within the field of ataxia. 6. National Ataxia Foundation Graduate Research Fellowship: The National Ataxia Foundation Graduate Research Fellowship is a competitive, non-renewable, merit-based award intended to encourage pre-doctoral students to pursue research and a career in the field of ataxia. 7. NAF Special Grants: Based on the emergent needs of the patient and research community, priority areas of ataxia research may be identified as eligible for specialized grant funding by NAF and may be awarded outside of the annual grant programs. In addition to NAF annual grants, NAF sponsors several clinical research programs that aim to drive advancements in the ataxia research field and prepare the ataxia community for future clinical trials. One of these programs is the Ataxia Tissue and Brain Donation Program. NAF and the University of Florida's Center for NeuroGenetics (CNG) work together to maintain a repository of brain and spinal cord tissue from ataxia donors. This tissue is available to SCA researchers to help advance our understanding of these diseases and to develop new therapies. NAF sponsors both the costs of tissue donation and maintenance costs of the brain and tissue bank.

    Expenses $1,562,162 · Grants $740,530

  • Funding for several of NAF's other key clinical research programs are provided through the NAF Drug Development Collaborative (DDC). The DDC is a pre-competitive pharmaceutical industry consortium with a principal goal of accelerating the development of treatments for ataxia. The Collaborative provides a centralized source for access to resources needed to support research and development of Ataxia therapies. Specific objectives of the Collaborative include natural history and bio sample data collection, development of biomarkers, validation of rating scales, clinical trial design, patient-reported outcomes, and other data necessary for the development and approval of safe and effective therapies. Two significant programs that are largely sponsored by the DDC include:1. No-cost Genetic Counseling and Testing Initiative: This program provides virtual genetic counseling and testing for individuals at-risk for three of the most common dominant ataxias to members at no-cost to participants. The aim of this program is to help individuals overcome barriers that have historically inhibited wide-spread genetic testing as well as support drug development through expanding the patient population eligible for future clinical trials.2. Clinical Research Consortium for the Study of Cerebellar Ataxia (CRC-SCA) Natural History Study: The CRC-SCA is one of the longest running and largest natural history studies of spinocerebellar ataxias (SCAs). A natural history study collects data that shows how a specific disease progresses in individuals over time. Natural history studies are essential for developing clinical trial designs that will facilitate drug development. There are over 300 patients enrolled at 16 CRC-SCA sites in the US and Canada. During annual visits, site investigators collect critical clinical data to aid in understanding disease progression and help guide future clinical trial design. Biofluids, such as plasma, serum, and cerebrospinal fluid, are also collected from patients and stored at the NINDS SCA-BRAC biorepository. Both deidentified clinical data and biofluids are available for request from non-participating investigators for approved research projects.

    Expenses $1,188,427 · Grants $982,290 · Revenue $570,833

As filed on the 2023 return. The filer continues this part on Schedule O, which is not shown here.

Listed in Part VII

  • Samuel Kirton

    President

    Total calculated
    $0
    Hours/week
    5
  • Linda Snider

    Vice President

    Total calculated
    $0
    Hours/week
    2
  • Greg Rooks

    Treasurer

    Total calculated
    $0
    Hours/week
    2
  • John Mauro

    Secretary

    Total calculated
    $0
    Hours/week
    2
  • David Brunnert

    Board Member

    Total calculated
    $0
    Hours/week
    2
  • Cindy DeMint

    Board Member

    Total calculated
    $0
    Hours/week
    2
  • Michael Cammer

    Board Member

    Total calculated
    $0
    Hours/week
    2
  • Jim Keene

    Board Member

    Total calculated
    $0
    Hours/week
    2
  • Greg Klassen

    Board Member

    Total calculated
    $0
    Hours/week
    2
  • Ann Riley

    Board Member

    Total calculated
    $0
    Hours/week
    2
  • Denise Kolpack

    Board Member

    Total calculated
    $0
    Hours/week
    2
  • John Dwyer

    Board Member

    Total calculated
    $0
    Hours/week
    2
  • Serena Hung

    Board Member

    Total calculated
    $0
    Hours/week
    2
  • Hayley McLoughlin

    Board Member

    Total calculated
    $0
    Hours/week
    2
  • David Spotts

    Board Member

    Total calculated
    $0
    Hours/week
    2
  • Mark Hazlin

    Board Member

    Total calculated
    $0
    Hours/week
    2
  • Andrew Rosen

    Chief Executive Officer

    Total calculated
    $199,072
    From this org
    $186,696
    From related orgs
    $0
    Other
    $12,376
    Hours/week
    40

    Schedule J breakdown matched by us

    Base
    $186,696
    Bonus
    $0
    Other
    $0
    Deferred
    $8,654
    Nontaxable benefits
    $3,722
    Filer's total
    $199,072
  • Joel Sutherland

    VP of Development

    Total calculated
    $159,390
    From this org
    $151,534
    From related orgs
    $0
    Other
    $7,856
    Hours/week
    40

    Schedule J breakdown matched by us

    Base
    $151,534
    Bonus
    $0
    Other
    $0
    Deferred
    $2,260
    Nontaxable benefits
    $5,596
    Filer's total
    $159,390
  • Lauren Moore

    VP and Chief Scientific Officer

    Total calculated
    $194,809
    From this org
    $189,726
    From related orgs
    $0
    Other
    $5,083
    Hours/week
    40

    Schedule J breakdown matched by us

    Base
    $189,726
    Bonus
    $0
    Other
    $0
    Deferred
    $3,180
    Nontaxable benefits
    $1,903
    Filer's total
    $194,809

Compensation is as filed in Part VII: reportable pay from this organization and from related organizations, other compensation, and hours per week. The total, marked calculated, is our sum of the three dollar columns, with a blank column counted as $0; the form itself has no total. On a Form 990-EZ the columns are Part IV's instead, and on a Form 990-PF Part VIII's — compensation, contributions to benefit plans, and expense account — and the total sums those. A Schedule J breakdown is as filed: base pay, bonus, other, deferred compensation and nontaxable benefits from this organization, with any from related organizations beside each, and the filer's own total. It is shown with the Part VII listing of the same name on the same return. The form gives no key between the two, so that pairing is ours, and is marked matched by us.

Schedule J

Answered yes

  • 2 · Substantiation required before reimbursing expenses
  • 3 · Approval by the board or compensation committee

Answered no

  • 4a · Severance or change-of-control payment
  • 4b · Supplemental nonqualified retirement plan
  • 4c · Equity-based compensation arrangement
  • 5a · Pay contingent on this organization's revenues
  • 5b · Pay contingent on a related organization's revenues
  • 6a · Pay contingent on this organization's net earnings
  • 6b · Pay contingent on a related organization's net earnings
  • 7 · Other non-fixed payments
  • 8 · Paid under the initial-contract exception

Part I's answers as filed. A line not listed was left unanswered; on lines 1a and 3 that means the box was not checked.

Grants on this return

The 10 largest by cash amount. The API serves every itemized grant.

Fundraising and gaming

From Schedule G of this return, as filed.

Had an agreement with a professional fundraiser (line 2a)
Not answered

Fundraising events (Part II)

Part II has at most four columns: the two largest events, the rest together, and the total.

Line Event 1 Walk n Roll Total
Gross receipts (line 1) $238,837 $238,837
Less contributions (line 2) $238,837 $238,837
Gross income (line 3) — —
Cash prizes (line 4) — —
Noncash prizes (line 5) — —
Rent and facility costs (line 6) $10,836 $10,836
Food and beverages (line 7) — —
Entertainment (line 8) — —
Other direct expenses (line 9) $135 $135
Direct expenses (line 10)
$10,971
Net income (line 11)
-$10,971

Activities outside the United States

From Schedule F of this return, as filed.

Offices (line 3c)
0
Employees, agents and contractors (line 3c)
0
Expenditures and investments (line 3c)
$404,800

At most 25 lines of each part are listed here. Schedule F names no grantee, so each line is a region and its money.

Activities by region (Part I)

Region Offices Employees Activity Specific services Expenditures
East Asia and the Pacific - Australia, Brunei, Burma, Cambodia, 0 0 Research grants to recipients in the region Research Grants $50,000
Europe (Including Iceland & Greenland) - Albania, Andorra, Austria, Belgium 0 0 Research grants to recipients in the region Research Grants $285,000
North America - Canada and Mexico, but not the United States 0 0 Research grants to recipients in the region Research Grants $69,800

Grants to organizations, by region (Part II)

The purpose of each grant is not shown.

Region Cash grants Manner of disbursement Noncash assistance Noncash description Valuation
North America - Canada and Mexico, but not the United States $19,800 Transfer $0 — —
North America - Canada and Mexico, but not the United States $50,000 Transfer $0 — —
Europe (Including Iceland & Greenland) - Albania, Andorra, Austria, Belgium $50,000 Transfer $0 — —
Europe (Including Iceland & Greenland) - Albania, Andorra, Austria, Belgium $100,000 Transfer $0 — —
Europe (Including Iceland & Greenland) - Albania, Andorra, Austria, Belgium $35,000 Transfer $0 — —
Europe (Including Iceland & Greenland) - Albania, Andorra, Austria, Belgium $50,000 Transfer $0 — —
East Asia and the Pacific $50,000 Transfer $0 — —
Europe (Including Iceland & Greenland) - Albania, Andorra, Austria, Belgium $50,000 Transfer $0 — —
Grantees recognized as charities or with a 501(c)(3) equivalency letter (Part II line 2)
8
Other grantees (Part II line 3)
0
Transferred property to a foreign corporation during the year (line 1)
No
Had an interest in a foreign trust (line 2)
No
Owned an interest in a foreign corporation (line 3)
No
Was a shareholder of a passive foreign investment company or qualified electing fund (line 4)
No
Owned an interest in a foreign partnership (line 5)
No
Had operations in or related to a boycotting country (line 6)
No

Provenance

Return type
form_990
Tax year
2023
Filed
26 April 2024
IRS schema version
2023v5.0
Source object
202431239349301653

Check it against the return as filed: the GivingTuesday Data Lake hosts a public copy of the original XML.

The source document this was parsed from is served over the API, which is where bulk and document access live.